Further evidence displayed that CAXIIis significantly increased the therapeutic effects (including suppressing tumor growth, attenuating tumor metastasis, and enhancing OS of mice) of anti–PD-1 antibodies on HCC compared to either single CAXII inhibitor group or single anti–PD-1 antibody group alone (P < 0.05) in vivo, respectively (47). Here, PDCD1 is linked to hepatocellular carcinoma.